Catalyst Pharmaceuticals Receives Prestigious Ranking on Forbes 2024 List of America's Most Successful Small-Cap Companies
05 déc. 2023 08h03 HE
|
Catalyst Pharmaceuticals, Inc.
CORAL GABLES, Fla., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Catalyst Pharmaceuticals, Inc. ("Catalyst" or "Company") (Nasdaq: CPRX) today announced its inclusion in Forbes' esteemed list of America's Most...
Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress
04 déc. 2023 16h35 HE
|
ALTERITY THERAPEUTICS LIMITED
MELBOURNE, Australia and SAN FRANCISCO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease
04 déc. 2023 07h25 HE
|
ALTERITY THERAPEUTICS LIMITED
- ATH434 improved motor performance and general function – - Webcast to be held this week to discuss new data and recent clinical progress – MELBOURNE, Australia and SAN FRANCISCO, Dec. 04,...
Global Stem Cells Market to surge at a CAGR of 11.6%, targeting an estimated value of USD 31,950 Million by 2030 as per Straits Research
30 nov. 2023 10h35 HE
|
Straits Research
New York, United States, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Recent advancements in stem cell therapies and tissue engineering have the potential to attract interest in the treatment of a variety of...
Harness Therapeutics secures additional £4 million funding to pursue physiological upregulation approach to treat neurodegenerative diseases
28 nov. 2023 04h00 HE
|
Harness Therapeutics
Harness, formerly operating as Transine, broadens its approach to physiological protein upregulation through post-transcriptional modulation of protein synthesisRefined focus on neurodegenerative...
Neurological Biomarkers Research Report 2023: A Global $18.75 Billion Market by 2030 with Pipeline Analysis of Alzheimer's, Parkinson's, Multiple Sclerosis, & Autism Spectrum Disorder
14 nov. 2023 05h28 HE
|
Research and Markets
Dublin, Nov. 14, 2023 (GLOBE NEWSWIRE) -- The "Neurological Biomarkers Market Size, Share & Trends Analysis Report By Application (Alzheimer's, Parkinson's, Multiple Sclerosis, Autism), By Type,...
Occlusion Devices Market Size Worth USD 5,588.20 Million by 2032 | Emergen Research
13 nov. 2023 12h30 HE
|
Emergen Research
Vancouver, Nov. 13, 2023 (GLOBE NEWSWIRE) -- The global occlusion devices market is projected to be worth USD 5,588.20 Million by 2032, according to a current analysis by Emergen Research. The...
Global Neurotoxin Market Report 2023: Sector is Expected to Reach $13.1 Billion by 2028
09 nov. 2023 04h43 HE
|
Research and Markets
Dublin, Nov. 09, 2023 (GLOBE NEWSWIRE) -- The "Neurotoxin Market Forecast to 2028 - Global Analysis By Product Type, Application, and End User" report has been added to ResearchAndMarkets.com's...
US Neurologists Emphasize Tremendous Unmet Treatment Need in Parkinson's Disease, According to Spherix Global Insights
07 nov. 2023 10h41 HE
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Parkinson's disease (PD) is the second-most prevalent neurodegenerative disorder following Alzheimer's disease, affecting an estimated one...
NeuroSigma Announces FDA 510(k) Submission for Second Generation Monarch eTNS System
07 nov. 2023 08h50 HE
|
NeuroSigma, Inc.
LOS ANGELES, Nov. 07, 2023 (GLOBE NEWSWIRE) -- NeuroSigma today announced it has submitted a 510(k) premarket notification to the U.S. Food and Drug Administration (FDA) for its second-generation...